Growth inhibitory and chemo-sensitization effects of naringenin, a natural flavanone purified from Thymus vulgaris, on human breast and colorectal cancer by Mohamed Salah I Abaza et al.
Abaza et al. Cancer Cell International  (2015) 15:46 
DOI 10.1186/s12935-015-0194-0PRIMARY RESEARCH Open AccessGrowth inhibitory and chemo-sensitization effects
of naringenin, a natural flavanone purified from
Thymus vulgaris, on human breast and colorectal
cancer
Mohamed Salah I Abaza1*, Khaled Y Orabi2, Ebtehal Al-Quattan1 and Raja’a J Al-Attiyah3Abstract
Background: Natural products with diverse bioactivities are becoming an important source of novel agents with
medicinal potential. Cancer is a devastating disease that causes the death of millions of people each year. Thus,
intense research has been conducted on several natural products to develop novel anticancer drugs.
Methods: Chromatographic and spectral techniques were used for the isolation and identification of naringenin
(Nar). MTT, flow cytometry, western blotting, Real Time PCR were used to test anticancer and chemosensitizing
effects of Nar, cell cycle, apoptosis, and expression of cell cycle, apoptosis, pro-survival and anti-survival-related
genes.
Results: In the present study, Thymus vulgaris ethanol extract was purified repeatedly to produce several compounds
including the known flavanone, Nar which was identified using different spectral techniques. Nar was shown to inhibit
both human colorectal and breast cancer cell growth in a dose- and time-dependent manner through cell cycle
arrest at S- and G2/M-phases accompanied by an increase in apoptotic cell death. Additionally, Nar altered the
expression of apoptosis and cell-cycle regulatory genes by down-regulating Cdk4, Cdk6, Cdk7, Bcl2, x-IAP and c-IAP-2
and up-regulating p18, p19, p21, caspases 3, 7, 8 and 9, Bak, AIF and Bax in both colorectal and breast cancer cells.
Conversely, it diminished the expression levels of the cell survival factors PI3K, pAkt, pIκBα and NFκBp65. Moreover,
Nar enhanced the sensitivity of colorectal and breast cancer cells to DNA-acting drugs.
Discussion: These findings provide evidence that Nar’s pro-apoptotic and chemo-sensitizing effects are mediated
by perturbation of cell cycle, upregulation of pro-apoptotic genes and down-regulation of anti-apoptotic genes
and inhibition of pro-survival signaling pathways.
Conclusion: In conclusion, Nar might be a promising candidate for chemoprevention and/or chemotherapy of
human cancers. However, further studies exploring this therapeutic strategy are necessary.
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Cancer is the leading cause of death in economically de-
veloped countries and the second leading cause of death
in developing countries [1]. The burden of cancer is in-
creasing in economically developed countries as a result
of population aging and growth and, increasingly, an
adoption of cancer-associated lifestyle choices, such as
smoking, physical inactivity, and unhealthy food.
Colorectal cancer is the third most commonly diag-
nosed cancer in males and the second in females, with
over 1.2 million new cancer cases and 608,700 deaths
estimated to have occurred in 2008 [2]. Breast cancer is
the most frequently diagnosed cancer and the leading
cause of cancer death in females worldwide, accounting
for 23% (1.38 million) of the total new cancer cases and
14% (458,400) of the total cancer deaths in 2008 [2].
Cancer is the second most common cause of death in
Kuwait after cardiovascular diseases [3]. It has been noted
that the age-adjusted incidence rates (AAIR) of colorectal
cancer among Kuwaiti males has increased by approxi-
mately 5-fold over the last 33 years and ranked the most
frequent site for the years 2003–2007. For Kuwaiti females,
breast cancer has the highest incidence among the Kuwaiti
population; breast cancer incidence has increased by 3-fold
over the last 33 years. Conversely, the incidence of colorec-
tal cancer has increased by approximately 4-fold. [3].
Cancer survival rates tend to be poorer in developing
countries, most likely because of a combination of a late
diagnosis and limited access to timely and standard
treatment. Cancer can be treated by chemotherapy,
radiation, surgery, monoclonal antibody therapy, and
other methods. However, the effectiveness of chemo-
therapy is often limited by their serious side effects [4].
Radiation may also affect normal tissues. Therefore,
complete removal of cancerous tissue without affecting
normal tissue is the major goal of treatment. Approxi-
mately 50-60% of cancer patients in the United States
utilize agents derived from different parts of plants or
nutrients (complementary and alternative medicine),
exclusively or concurrently with a traditional thera-
peutic regimen such as chemotherapy and/or radiation
therapy. The need for new drugs has promoted studies
evaluating possible anticancer agents in fruits, vegeta-
bles, herbs, and spices.
In recent years, dietary phytochemicals have received
the attention of various scientists for their action in treat-
ing various cancers [5]. Several studies have documented
that naturally occurring dietary phytochemicals inhibit
the growth of various cancer cells through the inhibition
of cell proliferation and the activation of apoptosis [6].
In particular, flavonoids, polyphenolic compounds that
occur naturally in the plant kingdom, display a wide
range of pharmacological properties, including antioxi-
dant and anti-carcinogenic activities [6-9].Thyme (Thymus vulgaris L., Family Lamiaceae), which
is known in Arabic as “zaatar or “zaitra”, is a pleasant-
smelling perennial shrub that grows in several regions
worldwide [10]. The plant is indigenous to the Medi-
terranean region and neighboring countries, Northern
Africa, and parts of Asia [11]. Thyme is widely used in
folk medicine for its expectorant, antitussive, anti-
bronchiolitis, antispasmodic, anthelmintic, carminative
and diuretic properties. The aromatic and medicinal
properties of the genus Thymus made it one of the most
popular plants worldwide. Thymus species have strong
antibacterial, antifungal, antiviral, and antioxidant activ-
ities [12]. Many pharmacological in vitro studies have re-
vealed the pharmacological activities of both thyme
essential oil and plant extracts [13]. Given the various
uses of thyme in traditional medicine and the hypothesis
that it may have anticancer activity, the present study
was undertaken to fractionate Thymus vulgarus in a
bioactivity-guided manner, to isolate and identify the
bioactive lead(s) that suppress(es) colorectal and breast
cancer cell growth, and to study the underlying intracel-
lular signal transduction pathways involved in regulating
cell cycle and apoptosis and its/their ability to potentiate
the chemo-sensitivity of colorectal and breast cancer
cells to DNA-acting drugs.
Methods
Cell lines
Human colorectal cancer cell lines (SW1116 and SW837),
human breast cancer cell lines (HTB26, HTB132), and
normal human fibroblast cells (CRL1554) were obtained
from American Type Culture Collection (ATCC; VA,
USA). SW1116, SW837, HTB26 and HTB132 cells were
cultured in 90% Leibovitz’s L15 medium supplemented
with 10% heat-inactivated fetal bovine serum and grown
at 37°C in a non-CO2 incubator. CRL1554 cells were cul-
tured in Eagle minimum essential medium, EMEM (90%)
supplemented with 10% heat-inactivated fetal bovine
serum and grown at 37°C in the presence of 5% CO2 and
95% ambient air.
Chemicals and reagents
Trypsin, Leibovitz's L-15 and EMEM medium, fetal bo-
vine serum (FBS), and penicillin/ streptomycin solution
(100×) were obtained from Mediatech, Inc. (Herndon,
VA, USA). An Annexin V-FITC apoptosis detection kit
was obtained from BD Hoffmann-La Roche Inc. (Nutley,
NJ, USA). A DNA-prep kit was obtained from Beckman
& Coulter (FL, USA). All reagents for RT-PCR and
real-time qPCR were obtained from Applied Biosystem
(Foster City, CA, USA). Nuclear/cytosol fractionation
kit was obtained from BioVision, Inc. (Moutain View,
CA, USA). Antibodies against PI3K, phospho-Akt1/2/3
(Ser473), Akt, NFκBp65, pIκBα and β-actin were purchased
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Cambridge, UK). All other reagents were purchased from
Sigma Chemicals (St Louis, MO, USA). Plasticware was
purchased from Falcon Lab (Franklin Lakes, NJ, USA).
General experimental procedure
Melting points were determined in open capillary tubes
using a Mettler 9100 electrothermal melting point ap-
paratus and were uncorrected. IR spectra were recorded
using a JASCO FTIR-4100 spectrophotometer. UV
spectra were measured in MeOH using a UV-160 IPC
UV-visible dual-beam spectrophotometer. The 1H and
13C NMR spectra were obtained on a Bruker Advance II
600-MHz spectrometer operating at 600 and 150 MHz,
respectively. Both 1H and 13C NMR spectra were re-
corded in methanol-d4, and the chemical shift values
were expressed in δ (ppm) relative to the internal stand-
ard TMS. For the 13C NMR spectra, spectral editing was
determined by DEPT. 2D NMR data were obtained
using the standard pulse sequence of the Bruker 600 for
COSY, HSQC and HMBC. Low resolution EIMS were
obtained using a double-focusing magnetic sector mass
spectrometer (GS-MS DFS/Thermo).
Plant material
Thymus vulgaris was obtained commercially from the
local market. Its identity was established as Thymus
vulgaris by Dr. KT Mathew of Kuwait University. A
voucher specimen was deposited at Kuwait University
Herbarium and given the number KTM & IYQ (5920).
Extraction and isolation
The dried ground plant (1.0 kg) was percolated at room
temperature with 96% EtOH (1 L × 3), and the extract
was evaporated in vacuo to leave 43 g of residue. Part of
this crude extract (10 g) was partitioned between water
and ethyl acetate. Part of the ethyl acetate fraction (2 g)
was chromatographed over a Si gel (190 g, 38 cm × 4 cm),
using 15% acetone in chloroform as the eluent, to yield,
after crystallization, 5.3 mg (0.01% yield) of pure Nar as
pale yellow needles. This process was scaled up to yield
Nar quantities enough for the study.
Time- and dose–dependent anti-proliferative effects of
Nar on human breast and colorectal cancer cells and
normal human fibroblast
Cell viability was measured using MTT assay, which is
based on the conversion of MTT to formazan crystals by
mitochondrial dehydrogenases [14]. Briefly, human colo-
rectal (SW1116, SW837) and breast (HTB26, HTB132)
cancer cell lines and normal human fibroblast cells
(CRL1554) were seeded (27 × 103 cells/well) in 96-well
plates and incubated in a non-CO2 or CO2 incubator for
18 h, depending on the cancer cell type and medium used.The cells were then treated with various concentrations of
Nar (0.05 - 4 mM) for 6–24 h. Untreated cells, to which
only DMSO was added at a final concentration of 0.2%,
were used as a control. MTT solution (5 mg/ml, filtered)
was added to the incubated cells (20 μl/well); the cells
were then incubated for another 4 h, and the medium
was discarded. DMSO (200 μl) was added to each well,
and absorbance was measured in a micro-plate reader
at a λ492 nm. The percentages of cell viability and cyto-
toxicity were calculated using the following equations: %
cell viability = (OD492 of treated sample/OD492 of un-
treated sample) × 100; % cytotoxicity = 100 - (OD492 of
treated sample/OD492 of untreated sample) × 100).
Colony forming assay
The antiproliferative effects of Nar on human colorectal
(SW1116 and SW837) and breast (HTB26 and HTB132)
cancer cell lines were confirmed using a colony-
formation assay. Briefly, cancer cells (5 × 105/well) were
plated in a 24-well plate and incubated at 37°C in a
non-CO2 incubator for 24 h. Thereafter, the cells were
treated with Nar (3 mM) and incubated at 37°C for
24 h. After that, untreated and treated human cancer
cells were collected by trypsinization and washed with
Hank's Balanced Salt Solution (HBSS), counted, and
plated in 24-well plates at 500 cells/well and incubated
at 37°C for 10–14 days. The colonies were washed with
cold phosphate-buffered saline (PBS), fixed with 100%
methanol, and stained with 0.5% crystal violet. The col-
onies were counted using an inverted microscope. The
data are presented as the number of colonies formed
with and without treatment.
Cell cycle analysis by flow cytometry
The distribution of cell-cycle phases (G0/G1, S, and G2/M)
was determined using flow cytometry by measuring
the DNA content of nuclei labeled with propidium iodide
as described previously [15]. Briefly, human colorectal
(SW1116 and SW837) and breast (HTB 26 and HTB132)
cancer cell lines were plated (5 × 105 cells/ml) in 24-well
plates and incubated at 37°C in a non-CO2 incubator for
18 h. The cells were then treated with Nar (3 mM) for
24 h. Untreated and treated human cancer cells were
collected by trypsinization, washed with cold phosphate-
buffered saline (PBS) and counted. Cells were processed
using a DNA-prep kit (Beckman & Coulter) and a DNA-
Prep EPICS workstation (Beckman & Coulter). During
this process, the cells were treated with a cell-membrane
permeabilizing agent (non-ionic detergent) followed by
propidium iodide (PI) and RNase. The samples were
incubated at room temperature for 15 min before ana-
lysis by flow cytometry (FC500, Beckman & Coulter).
The percentages of cells in different cell cycle phases
were calculated using the Phoenix statistical software
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Flow System, San Diego, CA).
DNA fragmentation assay
Induction of apoptosis was monitored using a DNA
fragmentation assay [16]. Briefly, human colorectal
(SW1116 and SW837) and breast (HTB 26 and HTB
132) cancer cell lines were plated (5 × 105 cells/ml) into
24-well plates and incubated at 37°C in non-CO2 incu-
bator for 18 h. Cells were treated with Nar (3 mM) and
then collected by trypsinization, washed with cold
phosphate-buffered saline (PBS) and centrifuged (1000 ×
g, 5 min). The cells were then resuspended in 200 μl of
DNA lysis buffer (10 mM EDTA, 0.5% Triton X-100,
0.5 mg/ml proteinase K and 50 mM Tris–HCl, pH 8).
The lysate was immediately incubated for 24 h at 56°C.
After adding phenol/chloroform/isoamyl alcohol (25:24:1)
to the lysate, DNA was precipitated with 100% ethanol.
The suspension was centrifuged, and the isolated DNA
was dissolved in 100 μl of TE buffer. The DNA samples
were then loaded onto a 1% agarose gel containing 0.1%
ethidium bromide and electrophoresed for 2 h at 70 V.
The DNA bands were visualized under UV illumination.
Annexin V/PI double staining assay for apoptosis
Induction of apoptosis was determined by Annexin V-
FITC apoptosis detection kit (BD Hoffmann-La Roche
Inc.) according to the manufacturer's instructions.
Briefly, human colorectal (SW1116 and SW837) and
breast (HTB26 and HTB132) cancer cell lines were
plated (5 × 105 cells/ml) in 24-well plate and incubated
at 37°C in a non-CO2 incubator for 18 h. The cells were
treated with Nar (3 mM) for 48 h. Cells from control
and treatment groups were re-suspended in 100 μl of
staining solution containing annexin V fluorescein and
propidium iodide in HEPES buffer (Annex V-FITC, BD
Pharmingen, San Diego, CA). Following incubation at
room temperature for 15 min, cells were analyzed by flow
cytometry. Annexin V binds to those cells that express
phosphatidylserine (PS) on the outer layer of the cell
membrane, and propidium iodide stains the cellular DNA
of those cells with a compromised cell membrane. This
technique allows for the discrimination of live cells
(unstained with either fluorochrome) from apoptotic
cells (stained only with annexin V) and necrotic cells
(stained with both annexin V and propidium iodide).
Western blot analysis
Expression of PI3K, phospho-Akt1/2/3 (Ser473), Akt,
NFκBp65, pIκBα and β-actin at the level of translation
was determined by western blot analysis as recently de-
scribed [15] with some modifications. Human colorectal
(SW1116) and breast (HTB26) cancer cell lines were
plated (5 × 105 cells/ml) in 24-well plates and incubatedat 37°C in a non-CO2 incubator for 18. The cells were
treated with Nar (3 mM) for 24 h. Untreated and Nar-
treated cancer cells were scraped from the wells and
collected by centrifugation (1000 × g, 5 min, 4°C). The
cells were then washed with ice-cold phosphate-buffered
saline (PBS) and re-centrifuged. Nuclear fraction (NFκB)
was prepared using cytosol/nuclear fractionation kit
(BioVision, Inc.) according to the manufacturer instruc-
tions. Whole cell extract (PI3K, phospho-Akt, Akt,
pIκBα and β-actin) was prepared as recently described
(15). Briefly, the cell pellets obtained were re-suspended
and lysed in buffer containing 20 mM Tris (pH 7.4),
200 mM sodium chloride, 1 mM ethylenediaminetetraa-
cetic acid (EDTA), 10 mM β-glycerophosphate, 10 mM
sodium pyrophosphate, 0.5% NP-40, 0.05% sodium deoxy-
cholic acid, and protease inhibitor cocktail, and the lysates
were clarified by centrifugation at 17000 × g for 30 min
at 4°C. Protein concentrations of nuclear fractions and
whole cell extracts were measured using the Bradford
assay (Bio-Rad, Hercules, CA). Untreated and Nar-
treated nuclear or whole cell extracts were mixed with
equal volumes of 5 × SDS sample buffer, boiled for
5 min, and separated by 10-12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). After
electrophoresis, proteins were transferred to polyvinyli-
dene difluoride (PVDF) membranes (Millipore, Billerica,
MA). The membranes were blocked in 5% nonfat dry milk
dissolved in PBST (3.2 mM Na2HPO4, 0.5 mM KH2PO4,
1.3 mM KCl, 135 mM NaCl, 0.05% Tween-20) overnight
at 4°C. Primary antibodies specific to PI3K, phosph-Akt1/
2/3 (Ser473), Akt, pIκBα and β-actin (Santa Cruz, CA)
were adsorbed to the membranes of whole cell extracts
and primary antibody specific to NFκBp65 was adsorbed
to the membrane of nuclear fractions. After washing with
PBS containing 0.1% Tween 20, the blots were incubated
with an alkaline phosphatase-conjugated species-specific
IgG secondary antibody for 2 h at room temperature.
Bound antibodies were detected using nitroblue tetrazo-
lium and bromochloroindoyl-phosphate. The specificities
of the antibodies used in this study were examined by test-
ing their reactivity with unrelated antigens, such as bovine
serum albumin (BSA). The signal intensities of the re-
spective bands were quantified by GS-800 calibrated im-
aging densitometer (Bio-Rad Laboratories, Inc. CA, USA).
Relative quantitative Real-Time PCR assay
mRNA expression of cell cycle- and apoptosis-associated
genes in control and Nar-treated cells was determined
by real-time polymerase chain reaction (qRT-PCR) using
an ABI 7000 SDS system (Applied Biosystems, USA)
and the comparative ΔΔCt method [15]. Commercial
assays that target specific genes with probes and primers
were obtained from Applied Biosystems. The targets and
their Applied Biosystems assay numbers for the cell-
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Hs00364847_m1); cdk6 (assay ID: Hs00608037_m1.);
Cdk7 (assay ID: Hs00361486_m1); p18 (assay ID:
Hs00176227_m1); p19 (assay ID: Hs00176481_m1); and
p21 (assay ID: Hs00355782_m1). The targets and their
Applied Biosystems assay numbers for the pro-apoptotic,
anti-apoptotic and caspase genes were as follows:
Bax (assay ID: Hs00180269_m1); Bak (assay ID:
Hs00832876_m1); AIF (assay ID: Hs00269879-m1);
c-IAP-2 (assay ID: Hs00985029_m1); Bcl2 (assay ID:
Hs00608023_m1); ×−IAP (Assay ID: Hs00236913_m1);
casp3 (assay ID: Hs00234387_m1); casp7 (assay ID:
Hs00169152_m1); casp8 (assay ID: Hs01018151-m1);
and casp9 (assay ID: Hs00154260_m1). GAPDH (assay
ID: Hs99999905_m1) was used as an endogenous
control to normalize the expression values for each
sample. For the comparative Ct method, we performed
a two-step RT-PCR to obtain cDNA and real-time
quantification using the target gene expression assays
and Taqman Universal Master Mix (Applied Biosys-
tems). Colorectal and breast cancer cells (5 × 105 cells/
ml) were plated in 24-well plates and incubated in a
non-CO2 incubator for 18 h. The cells were then
treated with Nar (3 mM) for 24 h. mRNA was ex-
tracted using the nucleospin RNAII ready-to-use sys-
tem (MACHEREY-NAGEL), and 200 ng/μl of mRNA
was used in the RT reaction. Contaminated DNA was
eliminated with DNase-I treatment for 20 min at 25°C,
followed by heat inactivation for 10 min at 65°C, prior
to cDNA synthesis using the high-capacity cDNA
reverse transcription kit (Applied Biosystems) accord-
ing to the manufacturer's instructions. For each sam-
ple, 2.5 μl of cDNA and 12.5 μl of Taqman Universal
Master Mix (2×) were used, and the final volume was
adjusted to 25 μl with nuclease-free water on an optical
96-well reaction plate (Applied Biosystems). Real-time
PCR was performed on an ABI 7000 SDS system using
ABI Prism's SDS collection software version 1.1 (Ap-
plied Biosystems). Real-time PCR conditions followed
the protocol given by the manufacturer of the Taqman
Universal Master Mix: step 1, 95°C for 10 min; step 2,
94°C for 15 s; and step 3, 60°C for 1 min. The samples
were analyzed using SDS collection software version
1.1, with the baseline set between 3 and 15 and the
threshold set at 0.2. The amount of target normalized
to an endogenous reference and relative to a calibrator
(untreated) was determined by 2-ΔΔCt, and the log
comparative Ct is presented graphically.
Nar enhances the anticancer effects of DNA-acting drugs
on colorectal and breast cancer cells
The potential of Nar to sensitize human colorectal
(SW1116, SW837) and breast (HTB26, HTB132) cancer
cells to DNA-acting drugs was studied as previouslydescribed [17]. Briefly, cancer cells were plated (27 × 103
cells/well) in 96-well plates at 37°C in a non-CO2 incuba-
tor. Eighteen hours after culture initiation, the cells were
simultaneously treated for 24 h with Nar (1.0 mM) and
various concentrations of the following DNA-damaging
drugs: camptothecin (CPT), 5-fluorouracil (5FU), doxo-
rubicin (DOX), cis-platin (CIP), ellipticine (ELP), and eto-
poside (ETP) at concentrations of 1 × 10−10 - 1 × 10−3
M; carboplatin (CAP) at concentrations of 1 × 10−10 -
1 × 10−4 M; and cyclophosphamide (CPA) at concen-
trations of 1× 10−11 - 1 × 10−5 M. The drugs were then
removed, the cells were washed with HBSS, and cell
growth was monitored using an MTT assay.
Statistical analyses
The results are expressed as the mean ± SEM of at least
three independent experiments. Statistical analyses were
performed with SPSS-21. The statistical significance of
the differences between the control and treated groups
were determined by one-way ANOVA. P values < 0.05
were considered significant.
Results
Isolation and identification of Nar
Nar was isolated as yellow needles (EtOAc-ether): mp
240–242°C; UV(MeOH) λmax (log ε) 240 (3.75) nm; IR
(KBr) νmax 3343, 1639, 1562, 1515, 1419 cm
−1; 1H NMR
(CD3OD, 600 MHz) see Table 1;
13C NMR (CD3OD,
150 MHz) see Table 1; EIMS (70 eV) m/z 272 [M]+.
Anti-proliferative effects of Nar on human colorectal and
breast cancer cells
To investigate the effect of Nar on human colorectal and
breast cancer cells, cell viability was studied using an
MTT assay. Treatment of human colorectal (SW1116,
SW837) and breast (HTB26, HTB132) cancer cell lines
with various concentrations of Nar (0.5-4 mM) for 6–
24 h showed time- and dose-dependent anti-proliferative
effects (Figure 1A, B). Treatment of SW1116 with Nar
for 6 and 12 h produced 42 ± 2.8% (Figure 1 Aa) and
52 ± 3.5% (IC50 = 4 mM) (Figure 1Ab) growth inhibition,
respectively. Nar did not show any effect on normal
human fibroblast cells (CRL1554) at 6 and 12 h, and the
difference between the effects of Nar on SW1116 and
CRL1554 was significant at 6 h (P ≤ 0.008) and non-
significant at 12 h (P ≤ 0.093). In addition, treatment of
SW1116 cells with Nar for 15 h markedly inhibited their
growth (% cytotoxicity = 0.0 - 98%, P ≤ 0.004, IC50 =
1.73 mM) compared with its effect on CRL1554 cells (%
cytotoxicity = 0.0 - 34%) (Figure 1Ac). Moreover, expos-
ure of SW1116 cells to Nar for 18 h showed significantly
greater (% cytotoxicity = 0.0 -99.4%, P ≤ 0.007, IC50 =
0.91 mM) growth inhibition than that exerted on
CRL1554 cells (% cytotoxicity = 0.0 - 26%) (Figure 1Ad).
Table 1 NMR Data of Nara
Position δH (m, J Hz) δC, m
b
2 5.33 (dd, 13.2, 3.0) 80.5, d
3 3ax 3.11 (dd, 13.2, 17.1) 44.0, t
3eq 2.69 (dd, 17.1, 3.0)
4 - 197.8, s
5 - 165.5, s
6 5.90 (d, 1.8) 96.2, d
7 - 168.4, s
8 5.89 (d,1.8) 97.1, d
9 - 164.9, s
10 - 103.4, s
1′ - 131.1, s
2′ 7.32 (dd, 7.2, 1.8) 129.1, d
3′ 6.83 (dd, 6.6, 2.4) 116.3, d
4′ - 159.0, s
5′ 6.83 (dd, 7.2, 1.8) 116.3, d
6′ 7.32 (dd, 7.2, 1.8) 129.1, d
OH 4.89 (s) -
aSpectra recorded in methanol-d4.
b 13C multiplicities were determined by
DEPT 135°.
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24 h produced a higher growth inhibition (% cytotox-
icity = 0.0- 100%, IC50 = 1.0 mM) than that produced on
CRL1554 cells (0.0 - 32%). The difference in the growth
inhibition was significant (P ≤ 0.015) (Figure 1Ae).
Treatment of SW837 with various concentrations of
Nar for 12 h produced a higher growth inhibition (% cyto-
toxicity = 0.0 - 55%, P ≤ 0.06, IC50 = 4.0 mM) than that
produced on CRL1554 cells (% cytotoxicity = 0 - 19%)
(Figure 1Ab). In addition, treatment of SW837 cells with
Nar for 15 h produced a higher cytotoxicity (% cytotox-
icity = 0.0 -99.5%, P ≤ 0.015, IC50 = 2.0 mM) than that
exerted on CRL1554 cells (% cytotoxicity = 0- 34%)
(Figure 1Ac). Moreover, exposure of SW837 cells to
Nar for 18 h markedly inhibited their proliferation (%
cytotoxicity = 0.0 – 99.9%, P ≤ 0.042, IC50 = 1.36 mM)
compared with its effect on CRL1554 cells (% cytotox-
icity = 0.0 - 26%) (Figure 1Ad). Further incubation of
SW837 cells with Nar for 24 h produced a higher growth
inhibition (% cytotoxicity = 0.0 - 100%, P ≤ 0.066, IC50 =
1.55 mM) than that produced on CRL1554 cells (% cyto-
toxicity = 0.0 - 32%) (Figure 1Ae).
Treatment of the human breast cancer cell line
HTB26 with Nar (0.2-4 mM) for 6 h exhibited a slight
growth inhibition (% cytotoxicity = 0 - 13%, P ≤ 0.897)
with no effect on CRL1554 cells (Figure 1Ba). A higher
growth inhibitory effect was observed on HTB132 cells
(% cytotoxicity = 0.0 - 52%, P ≤ 0.035, IC50 = 4.0 mM)
(Figure 1Ba.) after exposure to Nar for 6 h. Exposure ofHTB26 cells for 12 h produced a substantially higher
growth inhibition (% cytotoxicity = 0.0 – 73%, P ≤ 0.041,
IC50 = 3.09 mM) compared with CRL1554 cells (%
cytotoxicity = 0.0 – 19%). A similar growth inhibition
was noted with HTB132 cells treated with Nar for 12 h
(% cytotoxicity = 0.0 – 55%, P ≤ 0.038; IC50 = 3.73 mM)
(Figure 1Bb). Moreover, exposure of HTB26 to Nar
for 15 h markedly inhibited its growth (% cytotoxicity =
0.0 – 100%, P ≤ 0.001, IC50 = 1.36 mM) compared with
CRL1554 cells (% cytotoxicity = 0.0 – 34%). Exposure of
HTB132 cells to Nar for 15 h produced a higher anti-
proliferative effect (% cytotoxicity = 0.0 – 67%, P ≤ 0.007,
IC50 = 3.0 mM) than that produced on CRL1554 cells
(Figure 1Bc). In addition, exposure of HTB26 (% cyto-
toxicity = 0.0 – 99.6%, P ≤ 0.011, IC50 = 1.46 mM) and
HTB132 (% cytotoxicity = 0.0 – 95%, P ≤ 0.005, IC50 =
0.91 mM) cells to Nar for 18 h produced greater growth
inhibition than that observed in CRL1554 cells (% cyto-
toxicity = 0.0 – 26%) (Figure 1Bd). Furthermore, a simi-
lar significant growth inhibition was observed in HTB26
(% cytotoxicity = 0.0 – 99.9%, P ≤ 0.024, IC50 = 0.82 mM)
and HTB132 (% cytotoxicity = 0.0 – 95.3%, P ≤ 0.002, IC50
= 0.36) cells compared with CRL1554 cells (% cytotoxicity
0.0 – 32%) after a 24-h exposure to Nar (Figure 1Be).
The anti-proliferative effects of Nar on human colo-
rectal (SW1116, SW837) and breast (HTB26, HTB132)
cancer cells were confirmed by the inhibition of colony
formation. Treatment of SW1116 cells with Nar markedly
inhibited colony formation (mean number of colonies =
17 ± 2, P ≤ 0.0001) compared with untreated SW1116 cells
(mean number of colonies = 152 ± 1.84) (Figure 1Ca).
Additionally, exposure of SW837 cells to Nar greatly
inhibited colony formation (mean number of colonies =
9 ± 0.9, P ≤ 0.0001) compared with untreated SW837 cells
(mean number of colonies = 98 ± 2.6) (Figure 1Cb).
Exposure of HTB26 cells to Nar showed a marked inhib-
ition of colony formation (mean number of colonies =
11 ± 1.6, P ≤ 0.0001) compared with untreated HTB26
cells (mean number of colonies = 177 ± 3) (Figure 1Cc).
Similar marked inhibition of colony formation was
observed with Nar-treated HTB132 cells (mean number
of colonies = 22 ± 1.8, P ≤ 0.0001) compared with un-
treated HTB132 cells (mean number of colonies =
176 ± 3) (Figure 1Cd).
Nar arrests the growth of human colorectal and breast
cancer cells
To further demonstrate that the growth inhibition of
human colorectal and breast cancer cells leads to alter-
ations of the cell cycle distribution, cells were treated
with Nar and stained with PI. The percentage of cells in
each stage of the cell cycle was analyzed using flow
cytometry. Treatment of the human colorectal cancer cell
line SW1116 with Nar for 24 h resulted in accumulation
Figure 1 (See legend on next page.)
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Figure 1 Time and dose-dependent anti-proliferative effects and inhibition of colony formation of Nar on human colorectal and breast cancer
cell lines. Human colorectal cancer cells (SW1116, SW837) (A a-e), human breast cancer cells (HTB 26, HTB132) (B a-e) and normal human
fibroblast cells (CRL1554) (A, B a-e) were plated (27 × 103 cells/well) in 96-well plates in CO2 and non-CO2 incubators, depending on type of
media and cells, at 37°C for 18 h. The cells were then treated with various concentrations of Nar (0.05 – 4.0 mM) for 3–24 h. Cell growth was
monitored using an MTT assay. Untreated and Nar-treated colorectal cancer cells SW1116 (Ca), SW837 (Cb) and Nar-treated breast cancer
cells HTB26 (Cc), HTB132 (Cd) were trypsinized, counted and plated (500 cells /well) in 6-well plates. Following 10–14 days of incubation in
non-CO2 incubator at 37°C, the colonies were fixed and stained with crystal violet. The stained colonies were counted and compared with the
untreated control.
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treated; UT, P ≤ 0.005) and G2/M-phase (8.2% ± 1.3 vs.
5.6% ± 1.3 for UT, P ≤ 0.204) with a corresponding de-
crease in the fraction of cells in G0/G1 phase (37.8% ±
1.7 vs. 52.76% ± 1.2 for UT, P ≤ 0.001) (Figure 2Aa, b).
Furthermore, Nar growth-arrested SW837 cells in both
S-phase (48% ± 1.73 vs. 43.4% ± 1.96 for UT, P ≤ 0.123)
and G2/M-phase (14.7% ± 1.2 vs. 12.8% ± 1.1 for UT,
P ≤ 0.471) with a corresponding decrease of cells inFigure 2 Analysis of cell cycle perturbation of human colorectal and breas
human breast cancer cells (B) were plated (2.5 × 105 cells/well) into 24-wel
treated with Nar (3.0 mM) for 24 h. At least three samples were analyzed, a
represents the relative number of events, and the horizontal axis representG0/G1-phase (37.1% ± 1.2 vs. 43.7% ± 2.7 for UT, P ≤
0.045) (Figure 2Ac, d).
On the other hand, treatment of the human breast
cancer cell line HTB26 with Nar resulted in accumu-
lation of HTB26 cells in both S-phase (49% ± 1.2 vs.
47.1 ± 1.2 for UT, P ≤ 0.289) and G2/M-phase (13.7% ±
1.2 vs. 7.5% ± 1.4 for UT, P ≤ 0.013), with a correspond-
ing decrease of cells in G0/G1-phase (37.2% ± 1.7 vs.
45.3% ± 1.9 for UT, P ≤ 0.019) (Figure 2Ba, b). Additionally,t cell lines treated with Nar. Human colorectal cancer cells (A) and
l plates in a non-CO2 incubator at 37°C for 18 h. The cells were then
nd 20,000 events were scored for each sample. The vertical axis
s the fluorescence intensity.
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tion of HTB132 cells in S-phase (49.6% ± 2.3 vs. 45.4% ±
2.3 for UT, P ≤ 0.246) and G2/M-phase (14.6% ± 1.7 vs.
8.6% ± 1.2 for UT, P ≤ 0.035) with a corresponding de-
crease of cells in G0/G1-phase (35.7% ± 2.3 vs. 45.8% ± 2.3
for UT, P ≤ 0.021) (Figure 2Bc, d).
Nar induces apoptosis in human colorectal and breast
cancer cells
Agents with the ability to induce apoptosis in tumors
have the potential to be used for antitumor therapy. The
effect of Nar (3 mM) on the induction of programmed
cell death in human breast (HTB26 and HTB132) and
colorectal (SW1116 and SW837) cancer cell lines was
assessed with DNA fragmentation analysis. The results
from DNA gel electrophoresis showed the formation of
DNA laddering in both breast and colorectal cancer cell
lines treated with Nar (data not shown).Figure 3 Induction of apoptosis in human colorectal and breast cancer ce
breast cancer cells (B) were plated (2.5 × 105 cells/well) into 24-well plates
Nar (3.0 mM) for 48 h. The cells were processed and stained with annexin
and Methods section.To investigate the type of cell death induced by Nar,
cells were stained with annexin V-FITC/PI and analyzed
by flow cytometry. Annexin V is a Ca2+-dependent
phospholipid-binding protein possessing a high affinity
for PS, a membrane-bound component localized to the
inner surface of the cell membrane. An indicator of
early-stage apoptosis is the detection of exposed PS resi-
dues that have translocated to the cell surface. The
annexin V assay permits the simultaneous detection of
early apoptotic events based on annexin V binding to
exposed PS and late apoptotic/dead events through the
uptake of propidium iodide.
Treatment of SW1116 cells with Nar induced apop-
tosis, including early apoptosis (6.1% vs. 2.8% for UT),
late apoptosis (56.4% vs. 2.5% for UT) and necrosis
(29.9% vs. 1% for UT) (Figure 3Aa, b). Similar results
were obtained with SW837 cells treated with Nar, which
showed early apoptosis (3.7% vs. 3.5% for UT), latells treated with Nar. Human colorectal cancer cells (A) and human
in non-CO2 incubator at 37°C for 18 h. The cells were then treated with
V-FITC/PI and analyzed by flow cytometry as described in the Materials
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vs. 0.2% for UT) (Figure 3Ac, d). Moreover, exposure of
the human breast cancer cell line HTB26 to Nar in-
duced apoptosis, including early apoptosis (4.6% vs.
3.4% for UT), late apoptosis (95.2% vs. 2.4% for UT) and
necrosis (0.1% vs. 0.1% for UT) (Figure 3Ba, b). Similar
results were obtained with the breast cancer cell line
HTB132, in which Nar induced apoptosis with early
apoptosis (2.6% vs. 2.4% for UT), late apoptosis (97.1%
vs. 4.4% for UT) and necrosis (0.2% vs. 1.2% for UT)
(Figure 3Bc, d).
Nar affects the expression of Akt, pAkt, PI3K, pIκBα and
NFκBp65 in colorectal and breast cancer cells
Nuclear factor -κB (NF-κB), a major cell survival signal,
participates in multiple steps in cancer cell resistance to
chemical and radiation therapies. Studies with animal
models and cell culture systems have established links
between NF-κB and carcinogenesis, highlighting its
significance as a target in cancer treatment and chemo-
prevention [18]. We therefore tested the possibility
that Nar might inhibit NF-κB in colorectal and breast
cancer cells. Indeed, Nar inhibited the phosphorylation
of IκB, an upstream mediator of NF-κB function, and
thus, p65 localization into nuclear was also inhibited in
colorectal and breast cancer cells treated with Nar
(Figure 4a, b), supporting the involvement of NF-κB
inactivation in Nar-induced apoptosis. It is known that
PI3K and its downstream substrate Akt also have a role in
apoptosis [19]. We examined the expression of these
proteins, identifying dose-dependent reductions in PI3K
(Figure 4c), phospho-Akt (Figure 4d), Akt (Figure 4e)
and the ratio of pAkt/Akt in both colorectal and breast
cancer cell lines.
Nar modulates the expression of genes-related to cell cycle
and apoptosis in human colorectal and breast cancer cells
Inhibition of the cell cycle and the induction of apop-
tosis in cancer cells are two major goals in cancer treat-
ment. Therefore, we analyzed the expression of genes
controlling both cell cycle and apoptosis in human cancer
cells treated with Nar to elucidate the potential molecular
anticancer mechanisms of Nar, which remains unclear.
Cell cycle progression in eukaryotic cells is partly con-
trolled by the cyclin-dependent kinase (Cdk) family of
protein kinases, their activating partners, the cyclins,
and the cyclin-dependent kinase inhibitors (CdkIs) [20].
Our data showed that Nar differentially downregulated
the expression of Cdk4, Cdk6, and Cdk7 in the human
colorectal cancer cell lines SW1116 (Figure 5Aa) and
SW837 (Figure 5Ab) and in the human breast cancer
cell lines HTB26 (Figure 5Ba) and HTB132 (Figure 5Bb).
In contrast, Nar differentially upregulated the expression
of p18, p19, and p21 in both human colorectal cancer celllines, SW11116 (Figure 5Ac) and SW837 (Figure 5Ad),
and breast cancer cell lines, HTB26 (Figure 5Bc) and
HTB132 (Figure 5Bd).
On the basis of these observations, we propose that
alterations in the level of various cell cycle regulatory
proteins were responsible for the cell cycle arrest ob-
served in Nar-induced death in human colorectal and
breast cancer cells. Cell cycle arrest may, at least par-
tially, account for the induction of apoptosis and the
cytotoxic effects of Nar in human colorectal and breast
cancer cells.
Pro-apoptotic and anti-apoptotic proteins are central
regulators of apoptosis, and the interactions among
these proteins set the threshold for cell survival [21].
Nar differentially up-regulated the expression of the
pro-apoptotic genes, including caspases-3, 7, 8, 9,
Bak, AIF and Bax in SW1116 (Figure 6Aa) and SW837
(Figure 6Ab) as well as HTB26 (Figure 6Ba) and
HTB132 (Figure 6Bb). Meanwhile, Nar differentially
downregulated anti-apoptotic genes, such as Bcl2, x-
IAP and c-IAP-2, in both SW1116 (Figure 6Ac) and
SW837 (Figure 6Ad), as well as HTB26 (Figure 6Bc)
and HTB132 (Figure 6Bd). Nar promotes apoptosis in
human colorectal and breast cancer cells by altering
the ratio of pro and anti-apoptotic genes in favor of
apoptosis.
Nar enhances the sensitivity of colorectal and breast
cancer cells to DNA-acting drugs
The potential of Nar to potentiate the chemo-sensitivity
of colorectal and breast cancer cells to DNA-damaging
drugs was examined. The results are summarized in
Figures 7 and 8 and Table 2. The results reported in this
study clearly indicate the potential of Nar to increase the
sensitivity of colorectal and breast cancer cells to DNA-
damaging drugs. The synergistic and/or additive inter-
action between the tested DNA-acting drugs and Nar
needs to be further investigated and might be dependent
on the type of drug tested, the polymorphism of the
genes encoding the drug-metabolizing enzymes trans-
porters or drug targets.
Discussion
The need for new drugs has prompted studies evaluating
possible anticancer agents in fruits, vegetables, herbs,
and spices. Natural products with diverse bioactivities
are becoming an important source of novel agents with
pharmaceutical potential. The potential for plant ex-
tracts to act as anticancer therapeutic agents is due to
their ability to inhibit tumor growth, angiogenesis, and
metastasis with few side effects [22]. Much of this activ-
ity appears to stem from flavonoids, which are principal
components of many such extracts that demonstrate the
capacity to inactivate carcinogens, inhibit angiogenesis,
Figure 4 Expression of NKκB, pIκB, PI3K, Akt and pAkt in human colorectal and breast cancer cells treated with Nar. Colorectal (SW1116) and
breast (HTB26) cancer cells (2.5 × 105 cells/well) were plated into 24-well plates and incubated at 37°C for 18 h. The cells were then treated with
Nar (3 mM) for 24 h. Expression levels of NFκB/pIκB, in the nuclear extracts, (Aa, b and Ba, b); PI3K/pAkt/Akt (Ac-e and Bc-e) and β-actin (Af, Bf),
in the whole cell extracts, were detected by western blot analyses. The relative protein expression of NFκB/pIκB (C a, b) and PI3K, pAkt, Akt, pAkt/
Akt (Cc-f) was normalized to β-actin. *P ≤ 0.05 vs. control (untreated). The data were obtained from at least duplicate experiments.
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Figure 5 mRNA expression of cyclin-dependent kinase and cyclin-dependent kinase inhibitor genes in human colorectal and breast cancer cells
treated with Nar. The expression of cyclin-dependent kinase genes and cyclin-dependent kinase inhibitor genes in human colorectal (A) and breast
cancer cell lines (B) was determined by measuring mRNA levels through real-time RT-PCR and using the comparative ΔΔCt method to calculate
expression changes. The amount of the target, normalized to an endogenous reference and relative to calibrator, is given by 2 -ΔΔCt.
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Nar, the aglycone of naringin, is a flavonoid with activity
against uterine, blood, stomach, brain, and lung cancer cell
lines [24] with no toxic effect on normal cells [25,26]. Its
inhibitory effects on tumor growth have spurred interest
in its therapeutic application. However, the detailed mo-
lecular mechanisms of its anti-proliferative effects and
apoptosis induction on human colorectal and breast
cancer cells remained to be elucidated. In this study, we
endeavored to investigate the effects of Nar on human
colorectal and breast cancer cell growth, the intracellular
transduction pathways that regulate apoptosis and the
potential for Nar to enhance the sensitivity of both colo-
rectal and breast cancer cells to DNA-acting drugs.
The dried powdered Thymus vulgaris was percolated
repeatedly in 96% EtOH at room temperature. The com-
bined extracts were evaporated in vacuo until desicca-
tion. A total of 10 g of the dried residue was partitioned
successively, between water and ethyl acetate. Flash
chromatography of the ethyl acetate fraction over silica
gel, using 15% acetone in chloroform as an eluent,
yielded the known flavanone Nar [27] in addition to the
flavanonol aromadendrin [28], and Nar was isolated aspale yellow needles. Its molecular formula was deter-
mined as C15H12O5 on the basis of the ion peak at m/z
272 [M]+ and NMR data. Its IR spectrum showed
absorption bands for a hydroxyl group (3343 cm−1), a con-
jugated carbonyl group (1639 cm−1) and an aromatic
moiety (1562, 1515, and 1419 cm−1). The 1H and 13C
NMR spectra identified the possible identity of this
compound as a flavanone. The 13C NMR spectrum
showed fifteen carbon resonances distributed as a trip-
let, five doublets (two of them are of double intensity)
and seven singlets. The double intensity doublets reso-
nated in the aromatic region (at δC116.3 and 129.1,
Table 1), indicating the presence of a para-di-substituted
aromatic ring; two resonances of the remaining doublets
resonated, again, in the aromatic region of δC 96.2 and
97.1 (Table 1).
The coupling pattern and constants in the 1H NMR
spectrum confirmed the presence of 1,2,3,5-tetrasubsti-
tuted and 1,4-disubstituted aromatic rings (ring A and
ring B, respectively). The last doublet resonated in the
oxygenated aliphatic region at δC 80.5 ppm (C-2), while
the only triplet carbon resonated at δC 44.0 ppm (C-3).
This result confirmed the presence of a flavanone ring
Figure 6 mRNA expression of pro-apoptotic and anti-apoptotic genes in human colorectal and breast cancer cells treated with Nar. The expression of
pro-apoptotic and anti-apoptotic genes in human colorectal (A) and breast (B) cancer cells was determined by measuring mRNA levels through
real-time RT-PCR and using the comparative ΔΔCt method to calculate expression changes. The amount of the target normalized to an
endogenous reference and relative to calibrator, is given by 2 -ΔΔCt.
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C-2 (δC 80.5) and a proton resonated at δH 5.33 as a
double doublet with J = 13.2, 3.0 HZ (H-2). This coup-
ling constant and pattern are only possible when H-2
adapts an axial (β-) orientation. Ring B, however, is
attached to C-2 with an α-disposition. Therefore, the
absolute stereochemistry around C-2 was assigned as
S. The D2O-exchangeable sharp singlet resonating at δH
4.89 indicated the presence of at least one hydroxyl
group. Other HSQC, HMBC and COSY spectra facili-
tated the full unambiguous assignment of the protons
and carbons of this compound and revealed its identity
as the known flavanone Nar [27].
The anti-proliferative effects of Nar on colorectal
(SW1116, SW837) and breast (HTB26, HTB132) cancer
cells as well as normal human fibroblast CRL1554 cells
were investigated first. Nar was found to be cytotoxic to
both colorectal and breast cancer cells in a dose- and
time-dependent manner. CRL1554 human fibroblast
control cells were slightly affected by Nar. Therefore,
Nar appeared to reduce cancer cell growth with minimalcollateral damage. These results are in line with those
reported in other studies using Nar or Nar derivatives in
various cancer cell lines or animal models [29,30]. Our
results contradict the recent findings that Nar exhibits no
anti-cancer activity against human cervical cancer cells
[31]. Very recently, the nano-chemoprevention concept
was introduced as a novel approach for improving phy-
tochemical bioavailability and anti-tumor effects. Oral
administration of Nar-loaded nanoparticles (NARNPs) to
7,12-dimethylbenz(a)anthracene (DMBA)-treated animals
completely prevented tumor formation compared with the
free Nar and significantly reduced the degree of histo-
logical lesions, in addition to restoration of the status of
biochemical and molecular markers during oral carcino-
genesis [32]. NARNPs were found to have a more potent
antitumor effect than free Nar in completely preventing
the formation of squamous cell carcinoma and in restor-
ing the biochemical constituents to normal range [33].
Cell cycle arrest and apoptosis are two important
mechanisms involved in anti-cancer drug treatment [34].
Uncontrolled cellular proliferation is a hallmark of all
Figure 7 Nar enhances the chemosensitivity of human colorectal cancer cells to DNA-acting drugs. Human colorectal cancer cells SW1116 were plated
(27 × 103 cells/well) into a 96-well plate at 37°C in a non-CO2 incubator. At 18 h after starting the culture, the cells were treated for 24 h with Nar
(1 mM) and various concentrations of camptothecin, CPT doxorubicin, DOX, 5-fluorouracil, 5FU cisplatin, CIP, etoposide, ETP ellipticine, ELP
(1 × 10−10– 1 × 10−3 M), carboplatin, CAP (1 × 10−10 – 3.5 × 10−4 M) and cyclophosphamide, CPA (1 × 10−11 – 1 × 10−5 M). Cell proliferation
was monitored using an MTT assay.
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an effective strategy for eliminating cancer cells [35].
Many chemotherapeutic agents have been shown to im-
part anti-proliferative effects via arresting cell division at
certain checkpoints in the cell cycle [36]. The concept of
cell cycle-mediated apoptosis has gained increasing at-
tention, as targeting this pathway may provide an oppor-
tunity to overcome acquired drug resistance, decrease
mutagenesis and reduce toxicity [36].
In the present study, cell cycle arrest was observed
when cells were cultured with Nar. Characterization of
this effect demonstrated that expression levels of cell cycle
regulators were modulated by Nar treatment; arrestappeared to occur at S- and G2/M-phases in both colorec-
tal and breast cancer cells. These results are consistent
with those reported in other studies using different types
of malignancies [31].
Numerous studies have helped scientists appreciate
apoptosis as an ideal way to eliminate precancerous and/
or cancer cells [37]. However, most cancer cells block
apoptosis, which allows malignant cells to survive des-
pite genetic and morphologic transformation. Therefore,
searching for agents that can trigger apoptosis in tumor
cells has become an attractive strategy in anti-cancer
drugs discovery. Here, Nar markedly induced apoptosis
in both colorectal and breast cancer cell lines. The
Figure 8 Nar enhances the chemosensitivity of human breast cancer cells to DNA-acting drugs. Human breast cancer cells HTB26 were plated
(27 × 103 cells/well) into a 96-well plate at 37°C in a non-CO2 incubator. At 18 h after starting the culture, the cells were treated for 24 h with Nar
(1 mM) and various concentrations of camptothecin, CPT, doxorubicin, DOX, 5-fluorouracil, 5FU, cisplatin, CIP, etoposide, ETP, ellipticine, ELP (1 ×
10−10– 1 × 10−3 M), carboplatin, CAP (1 × 10−10 – 3.5 × 10−4 M) and cyclophosphamide, CPA (1 × 10−11– 1 × 10−5 M). Cell proliferation was moni-
tored using an MTT assay.
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shown the capability of Nar to stimulate apoptosis
in different cancer cell lines [24,31,38,39]. Moreover,
emerging evidence from literature has also demon-
strated that the anti-proliferative effect of natural products
is associated with apoptosis induction [40-42]. Again, the
results from this study are in line with these findings.
Taken together, dysregulation of the cell cycle mechanism
and the induction of cancer cell apoptosis are recognized
as an important goal of cancer therapy.It is known that PI3K and its downstream substrate Akt
have a role in apoptosis [43]. The expression of these
proteins was examined, identifying dose-dependent reduc-
tions of PI3K and phospho-Akt in both colorectal and
breast cancer cell lines. Total Akt protein levels remained
unchanged throughout the course of the experiment.
These results are in agreement with those documented
from other studies in other malignancies [42,44].
The PI3K/Akt signaling pathway is influential in the
regulation of cell survival due to the activation of anti-
Table 2 Percentage mean cytotoxicities of DNA-acting drugs and their combinations with Nar on human colorectal and
breast cancer cells
Treatment with DNA-acting drugs
and their combinations with Nar
Percentage mean cytotoxicitya Fold increase in therapeutic efficacy
SW837 HTB132 SW837b HTB132c
5 FU (1 × 10−10 - 1 × 10−3 M) 8 ± 1.0 54 ± 0.42
5 FU (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 50 ± 1.6 96 ± 0.44 6.25 1.7
CIP (1 × 10−10 - 1 × 10−3 M) 3 ± 0.8 49 ± 0.5
CIP (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 39 ± 2 80 ± 0.6 13 1.63
CAP (1 × 10−10 - 1 × 10−3 M) 9 ± 2 40 ± 2
CAP (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 27 ± 1.0 83 ± 1.5 3 2.1
CPT (1 × 10−10 - 1 × 10−3 M) 8 ± 1.1 60 ± 2.2
CPT (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 50 ± 2.6 95 ± 0.3 6.25 1.58
DOX (1 × 10−10 - 1 × 10−3 M) 6 ± 1.3 54 ± 1.3
DOX (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 41 ± 3 84 ± 0.6 6.83 1.56
CPA (1 × 10−11 - 1 × 10−4 M) 15 ± 2.6 44 ± 0.8
CPA (1 × 10-11 - 1 × 10-4 M) + Nar (0.5 mM) 47 ± 1.1 88 ± 1 3.13 2
ETP (1 × 10−10 - 1 × 10−3 M) 10 ± 2 51 ± 1.6
ETP (1 × 10−10 - 1 × 10−3 M) + Nar (0.5 mM) 57 ± 0.6 83 ± 0.93 5.7 1.63
ELP (1 × 10−11 - 1 × 10−4 M) 23 ± 2.5 51 ± 1.6
ELP (1 × 10−11 - 1 × 10−4 M) + Nar (0.5 mM) 70 ± 1.8 93 ± 0.6 3.04 1.82
aThe data are based on the mean of absorbance from 3 independent experiments.
b,cP-values of the combined treatments with DNA-acting drugs and Nar versus DNA-acting drugs = 0.0001.
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dependent inhibition of pro-apoptotic signals such as Bad,
caspase-9, and the family of Forkhead transcription factors
[46]. Akt inhibition results in the upregulation of FasL
expression in vascular smooth muscle cells and Hela cells
[47]. Downregulation of Akt leads to a decrease in the
phosphorylation of the endogenous Forkhead factors and
its location to the nucleus. It impairs the induction of FasL
promoter [46]. In addition, Akt promotes cell survival via
NF-κB activation [48]. The present study sought to deter-
mine the effects of PI3K/Akt on Nar-induced apoptosis.
The results showed that Nar down-regulated the PI3K/
Akt signaling pathway and that the PI3K/Akt pathway
inhibition may increase Nar-induced apoptosis. These data
are in accord with those reported in other studies in other
types of malignancies [29,42,44]
NF-κB participates in multiple steps in cancer cell resist-
ance to chemical and radiation therapies [18] highlighting
its significance as a target in cancer treatment and chemo-
prevention [49]. We therefore explored this transcription
factor as a target for the treatment of human colorectal
and breast cancer cells by using Nar. Our results indicate
that NF-κB is constitutively active in human breast and
colorectal cancer cell lines examined and that Nar down-
regulated the nuclear pool, or active form, of NF-κB and
suppressed IκBα phosphorylation and the expression of
the NF-κB-regulated gene products IκBα, Bcl2 and c-IAP-
2. This led to the suppression of proliferation andinduction of apoptosis. Nar appears to suppress IKK acti-
vation (under investigation) which leads to inhibition of
IκBα phosphorylation, as reported in the current study ab-
rogating IκBα degradation by ubiquitin-proteasome
pathway.
An imbalance between cell proliferation and cell death
due to cell cycle disruption will lead to cancer develop-
ment. Thus, the cell cycle could serve as a target for an-
ticancer agents to inhibit the uncontrolled proliferation
of cancer cells and initiate their apoptosis [50-52]. In the
present study, expression of cell cycle-regulatory genes
was assessed to understand the underlying molecular
mechanisms of Nar anticancer and apoptosis-inducing
effects. Human colorectal and breast cancer cells treated
with Nar exhibited a marked down-regulation in the
mRNA of genes related to cell cycle control, including
Cdk4, Cdk6 and Cdk7. However, the same treatment
resulted in the upregulation of cell cycle-dependent
kinase inhibitor genes, p18, p19 and p21. These results
are consistent with the findings in other types of malig-
nancies [31,42]. Increased levels of p18, p19, p21 and
maintenance of the key cell cycle regulatory proteins
that counter proliferation signals, eventually leading to
apoptosis, are possible mechanisms of colorectal and
breast cancer cell death induced by Nar.
Apoptosis is a cell suicide mechanism that is frequently
dysregulated in oncogenesis. Generally, apoptosis occurs
via two fundamental pathways: 1) the mitochondrial or
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pathway [53]. The intrinsic pathway is triggered by the
release of mitochondrial proteins, such as cytochrome c,
which bind to Apaf-1 and procaspase-9 in an ATP-
dependent manner to form the apoptosome [54]. The
apoptosome activates caspase-9, thereby initiating the
apoptotic caspase cascade [55]. Conversely, the extrinsic
pathway is initiated by the interaction of ligands with their
respective death receptors, sequentially leading to cleavage
of the initiator, caspase-8. Active caspase-8 cleaves the
executioner procaspase-3, resulting in apoptosis [56]. The
apical proteases in the intrinsic and extrinsic pathways are
caspase-9 and caspase-8, respectively. Activated caspase-8
and caspase-9 further initiate activation of the caspase cas-
cade, leading to biochemical and morphological changes
associated with apoptosis [57]. Caspase-3 is a well-known
downstream adaptor caspase that is proteolytically acti-
vated by caspase-9 or caspase-8 via mitochondrial or cell
death receptor signaling pathways [58]. Thus, caspases
have been shown to be activated during apoptosis in many
cells and play critical roles in both the initiation and exe-
cution of apoptosis [59]. To characterize the apoptotic
mechanisms induced by Nar, the expression of pro- and
anti-apoptotic proteins were assessed. The human colo-
rectal and breast cancer cells exposed to Nar displayed a
marked up-regulation in the mRNA expression of pro-
apoptotic genes including Caspases-3, 7, 8, and 9, Bak,
AIF and Bax. Meanwhile, the mRNA expression of the
anti-apoptotic genes including Bcl2, x-IAP and c-IAP-2
was differentially down-regulated in both colorectal and
breast cancer cells. These results are in agreement with
those findings in other malignancies [29,31,41,42,60].
Numerous studies have demonstrated that the Bcl-2
family significantly regulates apoptosis, either as an activa-
tor (Bax) or as an inhibitor (Bcl2) [61]. Bcl2 is a known
anti-apoptotic protein that is frequently examined for
potential clinical use as a prognostic biomarker in cancer,
and its overexpression is associated with resistance to
cytotoxic drugs such as cisplatin and 5-fluorouracil. In
addition, studies have shown that aberrant expression of
this protein facilitates tumor progression [62].
The results presented here demonstrated that Nar-
induced apoptosis relates to augmented levels of Bax and
down-regulation of Bcl2 inducing mitochondrial dysfunc-
tion and leading to apoptosis of colorectal and breast
cancer cells.
Bax is an essential mitochondrial-mediated apoptosis
activator, as its insertion in the mitochondrial membrane
results in the release of cytochrome c into the cytosol
leading to the activation of caspases and committing the
cells to apoptosis [63].
The caspase family, aspartate-specific cysteine proteases,
also plays a critical role in regulating apoptosis. Caspase
signaling is initiated and propagated by proteolyticautocatalysis and by the cleavage of downstream cas-
pases and substrates such as PARP and lamin A [64]. In
particular, caspase-3 is one of the key executioners of
apoptosis because it is either partially or totally respon-
sible for the proteolytic cleavage of many key proteins
that are important for cell viability [65]. Caspase-9 is an
initiator caspase in the apoptotic process, and its func-
tion is to activate the effector caspases 6, 7 and 3 [66].
Caspase-independent pathways are involved in mito-
chondrial dysfunction leading to release of AIF and
Endo G from mitochondria and apoptosis [66]. The
results from real-time PCR also showed that Nat pro-
moted AIF expression in both colorectal and breast
cancer cells, suggesting that Nar-induced apoptosis also
involves caspase-independent mechanisms.
The upregulation of pro-apoptotic genes in conjunc-
tion with the down-regulation of anti-apoptotic genes in
colorectal and breast cancer cells treated with Nar may
serve to shift the balance from pro-survival to pro-
apoptotic. Nar treatment, thus, may lower the threshold
of colorectal and breast cancer cells to pro-death signals,
thereby accounting for its anticancer effects. It is well
established that agents capable of inducing apoptosis as
a mode of cell death are good anticancer candidates
[67]. Therefore, Nar is a potential anticancer candidate
that is believed to selectively induce apoptosis in cancer
cells.
Chemotherapy is one of the main strategies to elimin-
ate residual cancer cells and prevent metastasis after sur-
gery or radiotherapy. The survival period and quality of
life of cancer patients have improved with the advent of
novel chemotherapeutic agents, such as docetaxel [68].
However, patients continue to suffer various toxic effects
including myelosuppression, vomiting and hypersensi-
tivity reactions. Meanwhile, the development of drug
resistance continues to threaten patient prognosis [69].
Chemotherapy may also sometimes aggravate cancer
progress and lead to patient death [70]. Recently, the
concept “to live in harmony with the tumor” has been
proposed. This notion has become a new direction in
cancer research [71]. In the present study, Nar markedly
reduced the apoptotic threshold of both colorectal and
breast cancer cells. These results encouraged us to evalu-
ate the potential of Nar to enhance the sensitivity of colo-
rectal and breast cancer cells to DNA-damaging drugs.
The results clearly indicated that simultaneous treat-
ment with Nar and DNA-acting drugs exhibited sub-
stantially higher cytotoxicity on both colorectal and
breast cancer cells compared with a single treatment
with a DNA-acting drug. Nar potentiates the chemo-
sensitivity of tested cancer cells in a drug- and cancer-
type dependent manner (Figures 6, 7, Table 2). These
results are in line with findings in other malignancies
[31,72,73].
Abaza et al. Cancer Cell International  (2015) 15:46 Page 18 of 19Thus, Nar has the potential to be a useful adjunct to
improve the effectiveness of chemotherapeutic agents in
the treatment of human cancers. Nar potentiates the
anticancer effects of DNA-acting drugs by activating
pro-apoptotic signaling, negating survival signaling, and
attenuating their side effects. Testing this strategy with a
larger number of cancer cell lines would increase the
value of this study. In addition, in vivo studies using
animal models are necessary to confirm the validity of
this combination strategy for the treatment of colorectal
and breast cancers and possibly other types of cancers.
Conclusions
The findings of the present study have important clin-
ical implications. This study demonstrated that Nar in-
duces apoptosis and potentiates the sensitivity of both
colorectal and breast cancer cells through multifactorial
mechanisms including cell cycle arrest, up-regulation of
the expression of pro-apoptotic genes, down-regulation
of anti-apoptotic genes and inhibition of pro-survival
signaling pathways. Nar therefore displays promise as
a pro-apoptotic factor that may benefit colorectal and
breast therapy. However, further studies should be
conducted in appropriate animal models of cancer, and
ultimately, human cancer prevention trials should be
performed.
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